NCI Study Targets Barriers to Colorectal Cancer Screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

BETHESDA, Md—National Cancer Institute researchers have begun the first national study aimed at identifying barriers to screening for colorectal cancer. Investigators from the Centers for Disease Control and Prevention and the Health Care Financing Administration are collaborating in the effort.

Questionnaires are being sent to a representative sample that includes 1,389 primary care physicians, 1,042 medical specialists, and 323 health plan medical directors. Researchers are seeking data on factors that may affect the use of screening and diagnostic follow-up in community practices. The study aims to assess the knowledge of physicians and their attitudes, practice patterns, and health plan guidelines for providing or promoting colorectal cancer screening.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content